Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 246, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.115010
Keywords
Mucormycosis; COVID-19; Amphotericin B (AmB); Azoles; Echinocandins; Statins; GPI biosynthetic Pathways; Antifungal agents
Categories
Ask authors/readers for more resources
Mucormycosis is a fungal infection that worsens over time if left undiagnosed and untreated. It is specifically associated with the current COVID-19 pandemic. Immuno-compromised patients are particularly vulnerable to both COVID-19 and mucormycosis. Risk factors for this infection include diabetes, corticosteroid medicines, and a weakened immune system. Treatments for mucormycosis are available but less effective, so researchers are focusing on promising agents such as liposomal amphotericin B, manogepix, echino-candins, isavuconazole, and posacanazole.
Mucormycosis is a fungal infection which got worsens with time if not diagnosed and treated. The current COVID-19 pandemic has association with fungal infection specifically with mucormycosis. Already immuno-compromised patients are easy target for COVID-19 and mucormycosis as well. COVID-19 infection imparts in weak immune system so chances of infection is comparatively high in COVID-19 patients. Furthermore, diabetes, corticosteroid medicines, and a weakened immune system are the most prevalent risk factors for this infection as we discussed in case studies here. The steroid therapy for COVID-19 patients sometimes have negative impact on the patient health and this state encounters many infections including mucormycosis. There are treatments available but less promising and less effective. So, researchers are focusing on the promising agents against mucormycosis. It is reported that early treatment with liposomal amphotericin B (AmB), manogepix, echino-candins isavuconazole, posacanazole and other promising therapeutic agents have overcome the burden of mucormycosis. Lipid formulations of AmB have become the standard treatment for mucormycosis due to their greater safety and efficacy. In this review article, we have discussed case studies with the infection of mucor-mycosis in COVID-19 patients. Furthermore, we focused on anti-mucormycosis agents with mechanism of action of various therapeutics, including coverage of new antifungal agents being investigated as part of the urgent global response to control and combat this lethal infection, especially those with established risk factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available